Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Table 1. Baseline characteristics 24hr preceding the study (Ramsook 2002)

Emesis episodes

Ondansetron group

Placebo group

less than 10

37(50%)

40(56.33%)

more than 10

37(50%)

31(43.66%)
Figuras y tablas -
Table 1. Baseline characteristics 24hr preceding the study (Ramsook 2002)
Ir a la tabla de la revisión
Table 2. Proportion of patients without vomiting (Ramsook 2002)

Time period

Ondansetron group

Placebo Group

ED Stay

64 (87%)

46 (65%)

First 24 hours

37 (58%)

30 (54%)

24 ‐48 hours

43 (70%)

30 (59%)
Figuras y tablas -
Table 2. Proportion of patients without vomiting (Ramsook 2002)
Ir a la tabla de la revisión
Table 3. Admission rate including the number requiring intravenous fluids (Ramsook 2002)

Ondansetron Group

Placebo Group

2

11
Figuras y tablas -
Table 3. Admission rate including the number requiring intravenous fluids (Ramsook 2002)
Ir a la tabla de la revisión
Table 4. Participants with no vomiting 0‐24hr (Cubeddu 1997)

Ondansetron(n=12)

Metoclopramide(n=12)

Placebo (n=12)

No vomiting

7 (58%)

4 (33%)

2 (17%)
Figuras y tablas -
Table 4. Participants with no vomiting 0‐24hr (Cubeddu 1997)
Ir a la tabla de la revisión